Minerva Neurosciences Says First Patient Screened In Confirmatory Phase 3 Clinical Trial Evaluating Roluperidone As Monotherapy For Treatment Of Negative Symptoms Of Schizophrenia

Minerva Neurosciences, Inc. has initiated its global confirmatory Phase 3 clinical trial for roluperidone, aimed at treating negative symptoms of schizophrenia, with the first patient screened. The trial will involve approximately 380 patients across 40 clinical sites worldwide, including the US and Europe. Efficacy topline data is expected in the second half of 2027. Roluperidone is noted as the only late-stage drug candidate addressing this high-need population, following positive results from prior pivotal trials.